Abstract: A backup storage includes a persistent storage for storing backups of entities and a backup data map. The backup storage also includes a backup manager that obtains a search request for data; obtains at least two data maps associated with at least two of the entities; generates the backup data map using the at least two data maps; searches the backups for the data using the backup data map to identify a copy of the data; and provides the copy of the data in response to the search request.

Abstract: The present disclosure relates to pyrrolobenzodiazepine (PBD) prodrugs and conjugates thereof. The present disclosure also relates to pharmaceutical compositions of the conjugates described herein, methods of making and methods of using the same.

Abstract: A backup storage includes a persistent storage and a backup manager. The persistent storage stores virtual machine level backups and application level backups. The backup manager obtains a request for a point in time restoration of an application; identifies, based on the application, a virtual machine level backup of the virtual machine level backups that is associated with: a virtual machine that hosted an instance of the application and a first point in time prior to a restoration point in time specified by the request for the point in time restoration; identifies, based on the application, an application level backup of the application level backups that is associated with the restoration point in time; generates a point in time backup using: the identified virtual machine level backup, and the identified application level backup; and services the request using the point in time backup.

Abstract: Embodiments are described for a heuristic configuration selection process as part of or accessible by the backup management process. This processing component provides a method to automatically determine the configuration parameters needed to obtain optimal performance for a given backup/restore job. This process involves identifying key parameters that determine backup performance and suggest means to derive and incorporate those configurable parameters into the backup software automatically. Embodiments can be applied to stream based backups, or other types of backup software as well.

Abstract: Methods are provided for treating cancers using a conjugate herein described as Conjugate 5, or a pharmaceutically acceptable salt thereof. Methods for treating cancers using Conjugate 5, or a pharmaceutically acceptable salt thereof, to target tumor associated macrophages are also described.

Abstract: The disclosure provided herein pertains to CCK2R-drug conjugates. In particular, the disclosure pertains to CCK2R-drug conjugates that target the delivery of drugs to a mammalian recipient. Also described are methods of making and using CCK2R-drug conjugates.

Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

Abstract: The disclosure provided herein pertains to CCK2R-drug conjugates. In particular, the disclosure pertains to CCK2R-drug conjugates that target the delivery of drugs to a mammalian recipient. Also described are methods of making and using CCK2R-drug conjugates.

Abstract: A sanitizer includes a shell defining first and second chamber portions, and having an opening into the first portion. A cover has a closed position over the opening for preventing access to the chamber, and an open position for permitting access to the chamber. A tray is moveable between an access position in the first portion, for placement and retrieval of an article within the tray, and a sanitizing position in the second portion, for exposing the article to sanitizing electromagnetic radiation from an emitter mounted in the second portion. A controller controls an actuator coupled to the tray to move the tray to the sanitizing position when the cover is closed, and to return the tray to the access position when a return condition is satisfied. A radiation barrier is configured to substantially prevent radiation from reaching the opening when the tray is in the access position.

Abstract: The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating folate receptor-expressing cancers with a folate-tubulysin conjugate. The invention described herein also relates to methods of treating folate-expressing cancers with a folate tubulysin conjugate in patients where stable disease results after treatment with the folate-tubulysin conjugate.

Abstract: The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating folate receptor-expressing cancers with a folate-tubulysin conjugate. The invention described herein also relates to methods of treating folate-expressing cancers with a folate tubulysin conjugate in patients where stable disease results after treatment with the folate-tubulysin conjugate.

Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.